PLUS1
3.77
-0.01 (-0.26%)
-0.01 (-0.26%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| OptiNose Inc | OPTN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.01 | -0.26% | 3.77 | 19:11:19 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 3.77 | 3.61 | 3.87 | 3.85 | 3.78 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 3.71 | 3.84 | 0.13 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,740 | 287,002 | $ 3.76 | $ 1,079,625 | 311,210 | 3.28 - 11.66 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:01:10 | formt | 100 | $ 3.83 | USD |
OptiNose Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 196.01M | 51.99M | 29.78M | $ 34.63M | $ - | -2.62 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
OptiNose News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/22/2020 | 07:01 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 10/22/2020 | 07:00 | GlobeNewswire Inc. | Optinose Announces Preliminary Third Quarter 2020 XHANCE Net.. |
| 10/07/2020 | 17:02 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 9/29/2020 | 09:30 | PR Newswire (US) | New Peer-Reviewed Data Highlight the Benefits of XHANCE in.. |
| 9/23/2020 | 16:48 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/21/2020 | 17:02 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 9/17/2020 | 17:01 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OPTN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.85 | 4.25 | 3.61 | 3.78 | 260,391 | -0.08 | -2.08% |
| 1 Month | 3.78 | 4.25 | 3.53 | 3.86 | 263,458 | -0.01 | -0.26% |
| 3 Months | 5.10 | 7.25 | 3.53 | 4.76 | 417,957 | -1.33 | -26.08% |
| 6 Months | 3.85 | 10.00 | 3.53 | 5.25 | 488,322 | -0.08 | -2.08% |
| 1 Year | 7.90 | 11.66 | 3.28 | 5.91 | 378,997 | -4.13 | -52.28% |
| 3 Years | 19.05 | 30.00 | 3.28 | 9.61 | 260,878 | -15.28 | -80.21% |
| 5 Years | 20.00 | 30.00 | 3.28 | 9.86 | 265,938 | -16.23 | -81.15% |
OptiNose Description
| OptiNose Inc is a US-based specialty pharmaceutical company which focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, which utilizes proprietary breath powered exhalation delivery system, to deliver a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids. The pipeline products of the company include XHANCE, OPN-300, OPN-021, and AVP-825. |
